Navigation Links
Webcast Alert: Isis Pharmaceuticals' Third Quarter 2013 Financial Results Conference Call
Date:10/29/2013

CARLSBAD, Calif., Oct. 29, 2013 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announces the following webcast:What:

Isis Pharmaceuticals' Third Quarter 2013 Financial Results and Highlights Conference CallWhen:

Tuesday, November 5, 2013 at 11:30 a.m. ET / 8:30 a.m. PTWhere:

www.isispharm.comHow:

Live on the Internet.  Simply log onto our website listed above. If you are unable to participate during the live event, a replay of the webcast will be available for a limited time at www.isispharm.com.

ABOUT ISIS PHARMACEUTICALS, INC.Isis is exploiting its leadership position in antisense technology to discover and develop novel drugs for its product pipeline and for its partners.  Isis' broad pipeline consists of 30 drugs to treat a wide variety of diseases with an emphasis on cardiovascular, metabolic, severe and rare diseases, including neurological disorders, and cancer.  Isis' partner, Genzyme, is commercializing Isis' lead product, KYNAMRO™, in the United States for the treatment of patients with HoFH.  Isis' patents provide strong and extensive protection for its drugs and technology.  Additional information about Isis is available at www.isispharm.com.

ISIS PHARMACEUTICALS' FORWARD-LOOKING STATEMENTThis press release includes forward-looking statements regarding Isis' business and the therapeutic potential of Isis' technologies and products in development.  Any statement describing Isis' goals, expectations, financial or other projections, intentions or beliefs is a forward-looking statement and should be considered an at-risk statement.  Such statements are subject to certain risks and uncertainties, particularly those inherent in the process of discovering, developing and commercializing drugs that are safe and effective for use as human therapeutics, and in the endeavor of building a business around such drugs.  Isis' forward-looking statements also involve assumptions that, if they never materialize or prove correct, could cause its results to differ materially from those expressed or implied by such forward-looking statements.  Although Isis' forward-looking statements reflect the good faith judgment of its management, these statements are based only on facts and factors currently known by Isis.  As a result, you are cautioned not to rely on these forward-looking statements.  These and other risks concerning Isis' programs are described in additional detail in Isis' annual report on Form 10-K for the year ended December 31, 2012, and its most recent quarterly report on Form 10-Q, which are on file with the SEC. Copies of these and other documents are available from the Company.

In this press release, unless the context requires otherwise, "Isis," "Company," "we," "our," and "us" refers to Isis Pharmaceuticals and its subsidiaries.

Isis Pharmaceuticals® is a registered trademark of Isis Pharmaceuticals, Inc.  Regulus Therapeutics™ is a trademark of Regulus Therapeutics Inc.  KYNAMRO™ is a trademark of Genzyme Corporation.

(Logo:  http://photos.prnewswire.com/prnh/20130807/LA60006LOGO)


'/>"/>
SOURCE Isis Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Webcast Alert: Heska Announces Third Quarter 2013 Earnings Conference Call Webcast
2. InRetail Peru to Host Third Quarter 2013 Earnings Conference Call & Audio Webcast
3. Neurocrine Biosciences Announces Conference Call And Webcast To Present Third Quarter 2013 Financial Results
4. AcelRx Pharmaceuticals to Hold Third Quarter 2013 Financial Results Conference Call and Webcast on November 5, 2013
5. Hill-Rom Holdings, Inc. Hosts Fiscal 2013 Fourth Quarter Earnings Conference Call and Webcast
6. BD Announces Live Webcast Of Fourth Fiscal Quarter Earnings Conference Call
7. Actavis, Inc. to Host Third Quarter 2013 Earnings Conference Call and Webcast
8. Isis Pharmaceuticals to Conduct Webcast and Conference Call to Discuss ISIS-APOCIII Rx Phase 2 Data
9. Pro-Dex, Inc. Announces Fiscal 2013 Fourth Quarter And Full-Year Financial Results Conference Call And Webcast
10. Bone Biologics to Webcast, Live, at RetailInvestorConferences.com on September 12th
11. Thoratec Presentation At Morgan Stanley 2013 Health Care Conference To Be Webcast
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/12/2016)... 2016 Indiso ltd ... ungedeckten medizinischen Bedarf bei Lungen- und Atemwegserkrankungen ... Forschungsprogramms bekannt. Das Programm, das sich mit ... respiratorischen Funktionen und anderer klinischer Parameter. ... das sich auf den ungedeckten medizinischen Bedarf ...
(Date:2/11/2016)... - Cardiac Marker Diagnostic ... and Cancer Therapy. - European Point of Care ... - Key Diagnostic Testing Markets. - Molecular ... Genetic Testing. - Molecular Diagnostics in Infectious Disease ... Diagnostic Products World Markets. - Point of Care ...
(Date:2/11/2016)... LONDON , Feb. 11, 2016 Stem ... that are characterized by self-renewal and the capacity to ... a relatively new discovery, as the first mouse embryonic ... it was not until 1995 that the first culturing ... pluripotent stem cells were not produced until 2006 As ...
Breaking Medicine Technology:
(Date:2/13/2016)... ... 13, 2016 , ... The National Association for Children of ... representing the growing community of recovering individuals (now over 23 million), to issue ... policies addressing addiction. , Although many of the presidential candidates of both ...
(Date:2/13/2016)... FL (PRWEB) , ... February 13, 2016 , ... The ... environmental impact of American businesses. , The increasingly modern world of instantaneous consumption ... often on non-renewable energy sources such as oil and coal, which pollutes our air, ...
(Date:2/13/2016)... ... ... Au Pair comes all the way around the world to provide child care ... often worried things won’t go well. More often than not, however, they find out their ... Year winner’s all commented how their Au Pairs have become a part of the family, ...
(Date:2/12/2016)... ... February 12, 2016 , ... According to an article published ... for a significant portion of hernia repairs throughout the United States. Commenting on this ... Center notes that this trend has not only been expected, but it seems to ...
(Date:2/12/2016)... Seattle, WA, and Washington, DC (PRWEB) , ... ... ... PATH and the Siemens Foundation today announced a new initiative—the Siemens ... technologies for low-resource settings. The partnership will recruit top students from U.S. ...
Breaking Medicine News(10 mins):